Can-Fite BioPharma Evaluates Earlier Interim Analysis for Key Liver Cancer Study
Can-Fite BioPharma reports longer survival in its Phase 3 liver cancer trial and raises $4 million through a warrant exercise.
Can-Fite's liver cancer medicine showed patients lived longer in early test results, and the company raised money to keep going. When a drug company shows patients living longer, it's a sign the medicine might actually work—watch to see if final results stay this good.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.